Pelvic Lymph Node Dissection in Prostate Cancer Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528-37. 12. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101. 13. Briganti A, Karakiewicz PI, Chun FK, Gallina A, Salonia A, Zanni G, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 2007;51:1573-81. 14. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in se- lect patients with prostate cancer. J Urol 1994;151:1315-20. 15. Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative pre- diction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998;159:2023-9. 16. Burkhard FC, Schumacher MC, Studer UE. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3:454-5. 17. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5. 18. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clin- ically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9. 19. Sartor O, McLeod D. Indium-111-capromab pendetide scans: an important test relevant to clinical decision making. Urology 2001;57:399-401. 20. Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, et al. Immunoscintigraphy with indium-111-capro- mab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999;54:1058-63. 21. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the pre- diction of nodal disease. Prostate Cancer Prostatic Dis 2002;5: 132-5. 22. Wawroschek F, Vogt H, Weckermann D, Wagner T, Harzmann R. The sentinel lymph node concept in prostate cancer - first re- sults of gamma probe-guided sentinel lymph node identification. Eur Urol 1999;36:595-600. 23. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001;166:1715-9. 24. Raghavaiah NV, Jordan WP Jr. Prostatic lymphography. J Urol 1979;121:178-81. 25. Whitmore WF 3rd, Blute RD Jr, Kaplan WD, Gittes RF. Radiocolloid scintigraphic mapping of the lymphatic drainage of the prostate. J Urol 1980;124:62-7. 26. Gil-Vernet JM. Prostate cancer: anatomical and surgical considerations. Br J Urol 1996;78:161-8. 27. Cellini N, Luzi S, Mantini G, Mattiucci GC, Morganti AG, Digesu C, et al. Lymphatic drainage and CTV in carcinoma of the prostate. Rays 2003;28:337-41. 28. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:29-37. 29. Dhar NB, Burkhard FC, Studer UE. Role of lymphadenectomy in 443 clinically organ-confined prostate cancer. World J Urol 2007;25: 39-44. 30. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169:145-7. 31. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lym- phadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681-6. 32. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease pro- gression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169: 849-54. 33. Weingärtner K, Ramaswamy A, Bittinger A, Gerharz EW, Vöge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996;156:1969-71. 34. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514-8. 35. Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T, et al. The template of the primary lymphatic land- ing sites of the prostate should be revisited: results of a multi- modality mapping study. Eur Urol 2008;53:118-25. 36. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 2001;166:2295-6. 37. Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, et al. Radical cystectomy with extended lymphadenectomy: eval- uating separate package versus en bloc submission for node pos- itive bladder cancer. J Urol 2007;177:876-81. 38. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol 2004;172:1286-90. 39. Kim SC, Jeong I, Song C, Hong JH, Kim CS, Ahn H. Biochemical recurrence-free and cancer-specific survival after radical prosta- tectomy at a single institution. Korean J Urol 2010;51:836-42. 40. Ham WS. Park SY, Rha KH, Choi YD. Outcomes of robotic prosta- tectomy for treating clinically advanced prostate cancer. Korean J Urol 2008;49:325-9. 41. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006;50:1006-13. 42. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:1798-803. 43. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L, et al. Pelvic lymphadenectomy can be omitted in se- lected patients with carcinoma of the prostate: development of a system of patient selection. Urology 1995;45:270-4. 44. Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf JS Jr, et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994;44: 519-24. 45. Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Korean J Urol 2011;52:437-445